The aim of the present study was to evaluate the effectiveness of fluorescence in situ hybridisation (FISH), as a screening test, in moderately- (G2) or poorly- (G3) differentiated breast cancers of the ductal (IDC) and lobular (ILC) histotypes and distant metastases. HER2 FISH was performed on 486 G2 and 477 G3 both of IDC and ILC histotypes and in 241 metastases. A significant difference in the HER2 amplification was observed between G2 (14.8%) and G3 (31.9%), with no difference according to the histotype. However, the rate of amplification increased to 36% in the G2/hormone receptor-negative cases as compared to 10.6% in the G2/receptor-positive cases (p<0.0001). HER2 was amplified in 17% of metastases with some differences depending on ...
Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cancer req...
HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed...
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastu...
The aim of the present study was to evaluate the effectiveness of fluorescence in situ hybridisation...
The aim of th present study was to evaluate the effectiveness of fluorescence in situ hybridisation ...
The aim of the present study was to evaluate the effectiveness of fluorescence in situ hybridisation...
Objective: To investigate the clinical application of the detection of HER-2 gene by fluorescence in...
BACKGROUND. Amplification of the HER-2/neu oncogene has been proposed as a target for antibody-based...
To investigate the concordance of detecting human epidermal growth factor receptor 2 (HER-2) status ...
In this study the detection of HER2 gene amplification was evaluated using Fluorescence In Situ Hybr...
Objective: The aim of this study was to show the usefulness of examining HER2 status on fluorescence...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to iden...
The HER-2/neu gene is amplified in 20-30\% of human breast cancers and has been shown to have progno...
Objective: To compare gene amplification of HER-2/neu gene by fluorescence in situ hybridization (F...
AbstractBackgroundThis project compared HER-2/neu gene status in breast cancers, as demonstrated by ...
Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cancer req...
HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed...
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastu...
The aim of the present study was to evaluate the effectiveness of fluorescence in situ hybridisation...
The aim of th present study was to evaluate the effectiveness of fluorescence in situ hybridisation ...
The aim of the present study was to evaluate the effectiveness of fluorescence in situ hybridisation...
Objective: To investigate the clinical application of the detection of HER-2 gene by fluorescence in...
BACKGROUND. Amplification of the HER-2/neu oncogene has been proposed as a target for antibody-based...
To investigate the concordance of detecting human epidermal growth factor receptor 2 (HER-2) status ...
In this study the detection of HER2 gene amplification was evaluated using Fluorescence In Situ Hybr...
Objective: The aim of this study was to show the usefulness of examining HER2 status on fluorescence...
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to iden...
The HER-2/neu gene is amplified in 20-30\% of human breast cancers and has been shown to have progno...
Objective: To compare gene amplification of HER-2/neu gene by fluorescence in situ hybridization (F...
AbstractBackgroundThis project compared HER-2/neu gene status in breast cancers, as demonstrated by ...
Eligibility for anti-human epidermal growth factor receptor 2 (HER2) treatments in breast cancer req...
HER2 amplification has been demonstrated in 15-25% of invasive breast carcinomas and can be assessed...
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastu...